These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 28159657)

  • 21. A retrospective, multicenter study of voriconazole trough concentrations and safety in patients with Child-Pugh class C cirrhosis.
    Wang T; Yan M; Tang D; Xue L; Zhang T; Dong Y; Zhu L; Wang X; Dong Y
    J Clin Pharm Ther; 2018 Dec; 43(6):849-854. PubMed ID: 29893015
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Necessity for a Significant Maintenance Dosage Reduction of Voriconazole in Patients with Severe Liver Cirrhosis (Child-Pugh Class C).
    Yamada T; Imai S; Koshizuka Y; Tazawa Y; Kagami K; Tomiyama N; Sugawara R; Yamagami A; Shimamura T; Iseki K
    Biol Pharm Bull; 2018 Jul; 41(7):1112-1118. PubMed ID: 29760306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of therapeutic drug monitoring of voriconazole in a pediatric population.
    Brüggemann RJ; van der Linden JW; Verweij PE; Burger DM; Warris A
    Pediatr Infect Dis J; 2011 Jun; 30(6):533-4. PubMed ID: 21127454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers.
    Cojutti P; Candoni A; Forghieri F; Isola M; Zannier ME; Bigliardi S; Luppi M; Fanin R; Pea F
    Basic Clin Pharmacol Toxicol; 2016 Jun; 118(6):474-9. PubMed ID: 26572687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic drug monitoring and use of an adjusted body weight strategy for high-dose voriconazole therapy.
    Richards PG; Dang KM; Kauffman CA; Stalker KL; Sudekum D; Kerr L; Brinker-Bodley M; Cheriyan B; West N; Collins CD; Polega S; Malani AN
    J Antimicrob Chemother; 2017 Apr; 72(4):1178-1183. PubMed ID: 28108679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral administration and younger age decrease plasma concentrations of voriconazole in pediatric patients.
    Kato K; Nagao M; Yamamoto M; Matsumura Y; Takakura S; Fukuda K; Ichiyama S
    J Infect Chemother; 2016 Jan; 22(1):27-31. PubMed ID: 26538245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic/Pharmacodynamic Analysis of Voriconazole Against Candida spp. and Aspergillus spp. in Allogeneic Stem Cell Transplant Recipients.
    Perez-Pitarch A; Guglieri-Lopez B; Ferriols-Lisart R; Pérez A; Ezquer-Garín C; Hernández-Boluda JC; Piñana JL; Navarro D; Solano C; Alós-Almiñana M
    Ther Drug Monit; 2019 Dec; 41(6):740-747. PubMed ID: 31136417
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections.
    Lamoureux F; Duflot T; Woillard JB; Metsu D; Pereira T; Compagnon P; Morisse-Pradier H; El Kholy M; Thiberville L; Stojanova J; Thuillez C
    Int J Antimicrob Agents; 2016 Feb; 47(2):124-31. PubMed ID: 26775563
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Voriconazole Dosing in Children Younger Than 3 Years Undergoing Cancer Chemotherapy or Hematopoietic Stem Cell Transplantation.
    Yan SQ; Seyboth B; Kobos R; Eaton A; Seo SK; Cohen N
    J Pediatric Infect Dis Soc; 2018 May; 7(2):169-171. PubMed ID: 28407118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients.
    Pieper S; Kolve H; Gumbinger HG; Goletz G; Würthwein G; Groll AH
    J Antimicrob Chemother; 2012 Nov; 67(11):2717-24. PubMed ID: 22796890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prophylactic administration of voriconazole with two different doses for invasive fungal infection in children and adolescents with acute myeloid leukemia.
    Sano H; Kobayashi R; Hori D; Kishimoto K; Suzuki D; Yasuda K; Kobayashi K
    J Microbiol Immunol Infect; 2018 Apr; 51(2):260-266. PubMed ID: 27329132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Voriconazole therapeutic drug monitoring: Factors associated with supratherapeutic and subtherapeutic voriconazole concentrations.
    You H; Dong Y; Zou Y; Zhang T; Lei J; Chen L; Wang X; Dong Y; Wang T
    Int J Clin Pharmacol Ther; 2018 May; 56(5):239-246. PubMed ID: 29393850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bioavailability of voriconazole in hospitalised patients.
    Veringa A; Geling S; Span LF; Vermeulen KM; Zijlstra JG; van der Werf TS; Kosterink JG; Alffenaar JC
    Int J Antimicrob Agents; 2017 Feb; 49(2):243-246. PubMed ID: 28012684
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A pharmacokinetic model for voriconazole in a highly diversified population of children and adolescents with cancer.
    Carlesse FAMC; de Araujo OR; Marques LMA; Silva DCBD; Senerchia AA; Petrilli AS
    Mycoses; 2019 Apr; 62(4):399-404. PubMed ID: 30687957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Voriconazole Therapeutic Drug Monitoring Practices in Intensive Care.
    van Wanrooy MJ; Rodgers MG; Span LF; Zijlstra JG; Uges DR; Kosterink JG; van der Werf TS; Alffenaar JW
    Ther Drug Monit; 2016 Jun; 38(3):313-8. PubMed ID: 26845112
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction.
    Calcagno A; Baietto L; Pagani N; Simiele M; Audagnotto S; D'Avolio A; De Rosa FG; Di Perri G; Bonora S
    Pharmacogenomics; 2014 Jul; 15(10):1281-6. PubMed ID: 25155930
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective CYP2C19-Guided Voriconazole Prophylaxis in Patients With Neutropenic Acute Myeloid Leukemia Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations.
    Hicks JK; Quilitz RE; Komrokji RS; Kubal TE; Lancet JE; Pasikhova Y; Qin D; So W; Caceres G; Kelly K; Salchert YS; Shahbazian K; Abbas-Aghababazadeh F; Fridley BL; Velez AP; McLeod HL; Greene JN
    Clin Pharmacol Ther; 2020 Mar; 107(3):563-570. PubMed ID: 31549389
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genotype-Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplantation.
    Teusink A; Vinks A; Zhang K; Davies S; Fukuda T; Lane A; Nortman S; Kissell D; Dell S; Filipovich A; Mehta P
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):482-6. PubMed ID: 26616742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic drug monitoring and safety of voriconazole in elderly patients.
    Cheng L; Xiang R; Liu F; Li Y; Chen H; Yao P; Sun F; Xia P
    Int Immunopharmacol; 2020 Jan; 78():106078. PubMed ID: 31830620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience.
    Racil Z; Winterova J; Kouba M; Zak P; Malaskova L; Buresova L; Toskova M; Lengerova M; Kocmanova I; Weinbergerova B; Timilsina S; Rolencova M; Cetkovsky P; Mayer J
    Mycoses; 2012 Nov; 55(6):483-92. PubMed ID: 22429709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.